Peptide Cycling Guide: How Long to Run BPC-157, TB-500, and GH Peptides (and When to Stop)

Last updated: June 6, 2026

Why Cycling Matters

Most cycling guides tell you to cycle everything for the same reason ("your receptors downregulate"), and that's only true for one group of peptides. There are actually two different reasons to cycle, and knowing which one applies tells you how strict to be.

Reason 1: real receptor desensitization (the GH peptides). Growth hormone secretagogues like CJC-1295 and Ipamorelin work by prodding your pituitary to pulse out GH. Hit that system non-stop and it pushes back: the pituitary gets less responsive to the same signal over time. This one is backed by actual research. Continuous exposure measurably blunts the GH response, while pulsed dosing keeps it working. For this group, cycling (or at least pulsing, like 5 days on and 2 off) genuinely protects the effect.

Reason 2: everything else, where cycling is precaution, not a reset. BPC-157, TB-500, GHK-Cu, and KPV don't act through a single receptor that fatigues, so the "your receptors get tired" line doesn't really apply to them. You cycle these for different reasons: to check whether the benefit is actually holding (or whether you've been masking something), to limit exposure to compounds that don't have long-term human safety data, and, for the copper ones, to keep cumulative copper in check.

The practical upshot: miss a cycle on a GH secretagogue and you're leaving results on the table. Run BPC-157 a couple weeks long and it's mostly a non-event.

Compound-Specific Cycling Protocols

BPC-157

BPC-157 is most commonly run for a specific injury. Once the injury has healed (or significantly improved), stop. If you're running it for general gut health or systemic recovery, cap your cycle at 8 weeks and take at least 2 weeks off before restarting.

Most community protocols follow 4 weeks on / 2 weeks off for mild issues, or 8 weeks on / 4 weeks off for chronic injuries. Longer cycles (12+ weeks) show diminishing returns in anecdotal reports.

TB-500

TB-500 is often used with a loading protocol: higher doses (2–5 mg/week) for the first 2-4 weeks, then dropping to a maintenance dose (750 mcg–2 mg/week) for another 4-8 weeks. Total cycle typically runs 6-12 weeks.

Off periods for TB-500 tend to be longer (4-8 weeks) because of its long-acting systemic effects. If you're stacking with BPC-157, you can stagger the cycles so you're never completely off both. See our BPC-157 vs TB-500 comparison.

CJC-1295 / Ipamorelin (GH Secretagogues)

GH secretagogues stimulate your pituitary to release growth hormone. The concern with extended use is pituitary desensitization. Your pituitary can produce less GH in response to the same signal over time, so cycling helps preserve responsiveness.

CJC-1295 with DAC has a longer half-life (~8 days) and may need longer off periods. CJC-1295 without DAC (mod GRF 1-29) clears quickly and is often stacked with Ipamorelin for synergistic GH release.

Track your cycles automatically

• Set on/off cycle timers for each compound
• Get alerts when it's time to cycle off
• Log notes to track effectiveness over time

Get Regimen Free

Tesamorelin

Tesamorelin is usually managed as a clinician-guided protocol, not a strict self-directed cycle. In practice, many people review results around the 8-12 week mark and adjust based on labs and symptoms.

If you include tesamorelin in a broader stack, keep your tracking disciplined: dose timing, symptom notes, and regular biomarker reviews matter more than fixed internet cycle templates.

KPV

KPV is the tail end of a hormone your body already makes (alpha-MSH), and people use it to calm inflammation. It's the "K" in KLOW. For chronic gut issues like ulcerative colitis or Crohn's, some run it longer: around 12 weeks on, 4 weeks off. Like BPC-157, KPV doesn't act on a receptor that fatigues, so the off-period is really about checking whether your inflammation stays down once you stop, not resetting anything.

MK-677 (Ibutamoren)

MK-677 is the odd one out. It's a GH secretagogue like CJC/Ipamorelin, but unlike the injectables, it doesn't desensitize your pituitary, studies have run it continuously for up to two years with GH and IGF-1 staying elevated the whole time. So the usual "cycle it or it stops working" logic doesn't apply here.

People still cycle it, but for a completely different reason: MK-677 raises blood sugar and insulin resistance over time, and it brings water retention and a big jump in appetite. So if you cycle MK-677, you're managing your metabolic health, not your GH response. Either way, keep an eye on your fasting glucose.

GHK-Cu: injectable and topical aren't cycled the same way

This one trips people up, because GHK-Cu comes two ways and they follow opposite rules.

• Injectable GHK-Cu: cycle it. Around 8–12 weeks on, 4–6 weeks off. The off-period is about cumulative copper, not receptors. A 1–2mg dose only carries roughly 160–320mcg of actual copper (well under dietary limits), but people take the break as a precaution and some monitor serum copper.
• Topical GHK-Cu (serums): no cycling needed, use it continuously. Almost no copper gets through intact skin, so a GHK-Cu serum is fine to run daily, indefinitely. (More on making and using one in our GHK-Cu serum guide.)

Cycling KLOW, GLOW & Other Blends

Blends are where cycling gets confusing, because now you're running three or four peptides on one schedule. Two of the most popular:

• GLOW = GHK-Cu + BPC-157 + TB-500. A standard 70mg vial is about 50mg GHK-Cu, 10mg BPC-157, and 10mg TB-500, so it's roughly 70% GHK-Cu by weight.
• KLOW = GLOW plus KPV. The standard 80mg vial adds 10mg of KPV (the "K") for extra anti-inflammatory action through a separate pathway.

Here's what makes cycling them simple: pace the cycle by the ingredient that needs it most, and in both blends that's the GHK-Cu. It's the bulk of the vial and it's the one carrying copper, so you don't cycle GLOW or KLOW on the BPC-157 timeline, you cycle them on the GHK-Cu timeline.

If you're running a blend mainly for skin or a low-grade nagging injury, the shorter end (6–8 weeks) is plenty. And remember what the off-period is doing here: it's a copper break and a chance to see if the benefit holds, not a receptor reset.

Compounds That Don't Need Cycling

Not everything needs to be cycled. Some medications are specifically designed for continuous, long-term use:

• GLP-1 agonists (semaglutide, tirzepatide): designed for continuous use. Stopping causes rebound appetite. See our GLP-1 maintenance guide for tapering strategies.
• Testosterone (TRT): continuous use under medical supervision. Cycling off TRT crashes your testosterone and can cause major side effects.
• HCG on TRT: often taken continuously alongside testosterone to maintain fertility/testicular volume.
• Thyroid medications: continuous prescribed use.
• Enclomiphene: typically continuous under medical supervision as a TRT alternative.

Signs You Need to Cycle Off

Even within recommended cycle lengths, pay attention to these signals that it's time for a break:

How to Track Your Cycles

The biggest mistake people make with cycling isn't the protocol. It's forgetting when they started or when they're supposed to stop. Here's what to track:

1. Cycle start date: when you took your first dose of this cycle
2. Planned cycle length: decide before you start, not mid-cycle when you "feel fine"
3. Off-period length: commit to the off-period. It's tempting to restart early.
4. Notes on effectiveness: log how you feel at weeks 2, 4, 6, and 8 to optimize future cycles.
5. Side effects: track side effects so you can adjust dose or duration next cycle

Never forget a cycle transition

• Cycle on/off alerts for every compound
• Dose logging with notes and side effects
• Progress photos tied to your protocol

Get Regimen Free

Quick Reference: Cycling Guidelines

Frequently Asked Questions